Francisco Ramírez-Valle

Money Moves

As of September 2026: Leading integration of Merida's programs into Lilly's immunology pipeline

Eli Lilly agreed to buy Merida Biosciences for up to $2.875 billion. The deal adds a platform that destroys the specific antibodies driving autoimmune disease instead of broadly suppressing the immune system. Merida's lead drug, MER511, is in early human testing for Graves' disease and thyroid eye disease.

Updated Sep 1